Regeneron Pharmaceuticals (REGN) Shares Outstanding (Diluted Average) (2010 - 2026)

Regeneron Pharmaceuticals has reported Shares Outstanding (Diluted Average) for 17 years, with the latest figure at $107.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) fell 3.15% year-over-year to $107.7 million; the trailing twelve-month figure through Mar 2026 stood at $107.7 million (down 3.15% YoY), and the FY2025 full-year result was $108.6 million, down 5.65% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $107.7 million, down from $108.6 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $115.6 million in Q3 2024, with the low at $107.7 million in Q1 2026.
• Average Shares Outstanding (Diluted Average) over 5 years is $112.7 million, with a median of $113.7 million recorded in 2023.
• Year-over-year, Shares Outstanding (Diluted Average) gained 2.89% in 2022 and dropped 5.8% in 2025.
• Tracing REGN's Shares Outstanding (Diluted Average) over 5 years: stood at $113.5 million in 2022, then gained by 0.18% to $113.7 million in 2023, then advanced by 1.23% to $115.1 million in 2024, then fell by 5.65% to $108.6 million in 2025, then dropped by 0.83% to $107.7 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $107.7 million (Q1 2026), $108.6 million (Q4 2025), and $108.9 million (Q3 2025), per Business Quant data.

Peer Comparison